Modification by drugs of urinary fibrin/fibrinogen degradation products in glomerulonephritis.
Treatment with indomethacin, aspirin, or prednisone has been shown to reduce urinary fibrin/fibrinogen degradation products (F.D.P.) in approximately two-thirds of patients with proliferative glomerulonephritis. This reduction which is dose-dependent for prednisone but not for indomethacin or aspirin in the range of doses used occurs within two to three days of beginning treatment and is thought to result from decreased intraglomerular fibrin deposition rather than alteration of glomerular permeability to F.D.P. In patients who responded in this manner treatment was associated with reductions in the degree of proteinuria and maintenance or improvement in renal function.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001241:Aspirin / Q000627:therapeutic use*; D002648:Child; D003404:Creatinine / Q000378:metabolism; D005260:Female; D005337:Fibrin / Q000378:metabolism / Q000652:urine*; D005340:Fibrinogen / Q000378:metabolism / Q000652:urine*; D005921:Glomerulonephritis / Q000188:drug therapy* / Q000378:metabolism / Q000652:urine; D006801:Humans; D007213:Indomethacin / Q000627:therapeutic use*; D007678:Kidney Glomerulus / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D010958:Plasminogen / Q000097:blood; D011241:Prednisone / Q000627:therapeutic use*; D011507:Proteinuria / Q000188:drug therapy; D013997:Time Factors; D014508:Urea / Q000097:blood
D014508:Urea; D005337:Fibrin; D005340:Fibrinogen; D010958:Plasminogen; D003404:Creatinine; D001241:Aspirin; D011241:Prednisone; D007213:Indomethacin